- Home
- SSP vs ACRS Comparison
SSP vs ACRS Comparison
Compare SSP & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSP
- ACRS
- Stock Information
- Founded
- SSP 1878
- ACRS 2012
- Country
- SSP United States
- ACRS United States
- Employees
- SSP N/A
- ACRS N/A
- Industry
- SSP Broadcasting
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- SSP Industrials
- ACRS Health Care
- Exchange
- SSP Nasdaq
- ACRS Nasdaq
- Market Cap
- SSP 158.9M
- ACRS 170.9M
- IPO Year
- SSP 1988
- ACRS 2015
- Fundamental
- Price
- SSP $2.38
- ACRS $1.40
- Analyst Decision
- SSP Buy
- ACRS Strong Buy
- Analyst Count
- SSP 2
- ACRS 7
- Target Price
- SSP $6.25
- ACRS $11.67
- AVG Volume (30 Days)
- SSP 2.8M
- ACRS 1.2M
- Earning Date
- SSP 05-08-2025
- ACRS 05-06-2025
- Dividend Yield
- SSP N/A
- ACRS N/A
- EPS Growth
- SSP N/A
- ACRS N/A
- EPS
- SSP 1.01
- ACRS N/A
- Revenue
- SSP $2,509,772,000.00
- ACRS $18,720,000.00
- Revenue This Year
- SSP N/A
- ACRS N/A
- Revenue Next Year
- SSP $9.18
- ACRS $425.96
- P/E Ratio
- SSP $2.36
- ACRS N/A
- Revenue Growth
- SSP 9.46
- ACRS N/A
- 52 Week Low
- SSP $1.36
- ACRS $0.95
- 52 Week High
- SSP $4.65
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- SSP 44.72
- ACRS 26.99
- Support Level
- SSP $3.07
- ACRS $1.57
- Resistance Level
- SSP $3.81
- ACRS $1.59
- Average True Range (ATR)
- SSP 0.36
- ACRS 0.10
- MACD
- SSP -0.09
- ACRS 0.01
- Stochastic Oscillator
- SSP 4.67
- ACRS 13.79
Stock Price Comparison Chart: SSP vs ACRS
About SSP E.W. Scripps Company (The)
The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.